10q10k10q10k.net
Neuronetics, Inc.

Neuronetics, Inc.STIMEarnings & Financial Report

Nasdaq

Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology. 

STIM Q3 2025 Key Financial Metrics

Revenue

$37.3M

Gross Profit

$17.1M

Operating Profit

$-7.3M

Net Profit

$-9.0M

Gross Margin

45.9%

Operating Margin

-19.6%

Net Margin

-24.3%

YoY Growth

101.3%

EPS

$-0.13

Financial Flow

Neuronetics, Inc. Q3 2025 Financial Summary

Neuronetics, Inc. reported revenue of $37.3M for Q3 2025, with a net profit of $-9.0M (-24.3% margin). Cost of goods sold was $20.2M, operating expenses totaled $24.4M.

Key Financial Metrics

Total Revenue$37.3M
Net Profit$-9.0M
Gross Margin45.9%
Operating Margin-19.6%
Report PeriodQ3 2025

Neuronetics, Inc. Annual Revenue by Year

Neuronetics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $74.9M).

YearAnnual Revenue
2024$74.9M
2023$71.3M
2022$65.2M

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$20.3M$17.4M$16.4M$18.5M$22.5M$32.0M$38.1M$37.3M
YoY Growth11.6%12.1%-6.6%3.6%10.7%83.6%131.7%101.3%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$115.8M$103.8M$96.8M$74.1M$140.9M$142.0M$134.7M$145.5M
Liabilities$81.6M$76.2M$77.4M$64.7M$109.1M$102.5M$103.1M$114.1M
Equity$34.2M$27.7M$19.4M$9.4M$27.7M$35.5M$27.1M$27.4M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$2.1M$-12.0M$-5.0M$-5.4M$-8.6M$-17.0M$-3.5M$-785000